BioGeneration Capital Fund III C.V.: providing fresh capital to innovative Dutch and other European Life Sciences companies. The fund has a target size of EUR 50 million.
In addition to Dutch and UK based family offices, other existing investors such as Topfonds Gelderland (a fund managed by PPM Oost) and LEH Holding (holding company of Leiden University) joined the new fund. New investors also include InnovationQuarter. The fund will provide the necessary seed and growth capital to fund 12 to 14 promising life sciences companies in Europe, with a strong focus on Dutch companies.
BioGeneration Ventures typically invests in companies that develop new and innovative therapeutics, medical devices and diagnostics for human use that will contribute to improved and more cost-effective healthcare.
The new fund will further build on the successful strategy of the first two BGV funds that yielded major successes including Dezima Pharma and Acerta Pharma. Both companies were co-founded by BGV and were sold within three years at multi-billion dollar valuations. These companies were typical examples of the biotech sector’s ability to generate so-called “unicorns” delivering outsized returns for investors.
- Edward van Wezel, Managing Partner: “It’s a mark of the quality of our first two BGV funds that existing investors have swiftly recommitted to our new fund, and that new investors have already joined the initial close. This first close exceeds the size of our previous funds and will enable us to build an exciting portfolio of highly innovative companies.”
Together with the first close of the new Fund, two seasoned professionals have joined BGV’s investment team:
- Oskar Slotboom has joined as Partner. Oskar held senior positions in healthcare and industrial biotech at Johnson & Johnson, Crucell and Avantium after starting his career at McKinsey & Company.
- Rob de Ree has joined as Operating Partner. Rob is the former CEO of Dezima Pharma and had senior leadership positions in large and small medical device companies including Medtronic and BMEYE. After integrating Dezima into Amgen post-acquisition, in his new role he will provide operational and entrepreneurial experience to BGV portfolio companies and management teams.